SecBot SecBot

YARW drug pipeline

Yarrow Bioscience, Inc. · 1 rated drug
$14.27
+2.4% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2a/2b (dosing initiated ~July 27, 2026); Phase 1 SAD in thyroid eye disease previously reported
Time to marketUnknown — mid-stage. If the Phase 2a/2b trial succeeds and later registrational studies follow, approval would be several years away (late 2020s at the earliest); the company currently has no approved products.

YB-101 Updated Aug 17

What to watch

YB-101 is a Phase 2a/2b, single-asset bet at a company (Nasdaq: YARW, formerly VYNE) that just closed a reverse merger, raised ~$200M, and began dosing the pivotal-to-next-stage trial, but the defining data readout is not expected until 2H 2027. A non-medical investor should treat YARW as a speculative, liquidity-thin clinical stock: watch for interim Phase 2a/2b data, the exact readout date, and any competitive readouts from anti-FcRn/IgG-degrading drugs in Graves'/thyroid eye disease.

Bull case
  • Potential first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with FDA Fast Track designation for Graves' disease (Yarrow investor presentation filed July 14, 2026, SEC accession 000110465926083359).
  • Early data cited by the company: Phase 1 SAD in thyroid eye disease showed no SAEs, no hearing/hyperglycemia AEs, and dose-dependent proof of mechanism, 66.7% ORR and proptosis improvement vs 10-20% placebo (per the same investor presentation).
  • ~$200M raised to date (including pre-closing financing) funds operations into 2028; merger closed July 27, 2026 and dosing in the Phase 2a/2b trial began immediately (company announcement in event ledger; SEC 425 filings).
Bear case
  • Single-asset, no-revenue clinical company: the next defining binary (Phase 2a POC data) is guided for 2H 2027, roughly a year-plus away with no precise date, so there is no near-term hard catalyst (SEC 425 report; impact rubric).
  • Early-stage clinical risk: Phase 2a may fail to replicate Phase 1 signals, and competing biologics (anti-FcRn, IgG degraders) are also advancing in Graves'/thyroid eye disease (risk section of the July 14, 2026 8-K/425 analysis).
  • The legacy VYNE shell contributed no commercial assets: its only locally ingested trial is a TERMINATED Phase 2 vitiligo study of VYN201 (ClinicalTrials.gov NCT06493578), and pre-merger VYNE holders were diluted to ~3% of the combined company.